CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121

February 3rd 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

Tisagenlecleucel Responses in Pediatric ALL Sustained With Longer Follow-up

February 1st 2018

At a median follow-up of 13.1 months, tisagenlecleucel (Kymriah) induced an overall remission rate of 81% in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Locke Highlights Axi-Cel/Atezolizumab Data in DLBCL

February 1st 2018

Frederick L. Locke, MD, discusses the initial data for axicabtagene ciloleucel (axi-cel; Yescarta) plus atezolizumab (Tecentriq) in diffuse large B-cell lymphoma, and reflected on the long-term survival data from the ZUMA-1 trial.

Dr. Perales on Treatment With Approved CAR T-Cell Therapy

January 31st 2018

Miguel-Angel Perales, MD, Deputy Chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses determining which chimeric antigen receptor (CAR) T-cell therapy to use for patients with hematologic malignancies.

ASCO Names CAR T-Cell Therapy as Cancer Advance of the Year

January 30th 2018

The annual update on oncology treatment highlights the most impactful clinical cancer research and policy developments over the past year in CAR T-cell therapy.

Liso-Cel Highly Active in Relapsed/Refractory DLBCL

January 30th 2018

David G. Maloney, MD, PhD, discusses the promise of lisocabtagene maraleucel in patients with diffuse large B-cell lymphoma.

CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Myeloma

January 30th 2018

Jesus Berdeja, MD, discusses ongoing research with bb2121 in patients with relapsed/refractory myeloma.

Dr. Locke on the ZUMA-6 Trial of Axi-Cel With Atezolizumab for DLBCL

January 26th 2018

Frederick Locke, MD, Moffitt Cancer Center, discusses the results of the ZUMA-6 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab (Tecentriq) for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL).

Advances and Research Needs in Lymphoma

January 26th 2018

Investigating CAR T-Cell Therapy in Lymphoma

January 26th 2018

Approval of Acalabrutinib in Mantle Cell Lymphoma

January 26th 2018

Duration of Rituximab Maintenance in FL

January 26th 2018

Long-Term Data With Copanlisib in Follicular Lymphoma

January 26th 2018

Follicular Lymphoma: Obinutuzumab and Chemotherapy

January 26th 2018

MAVORIC Trial in Cutaneous T-Cell Lymphoma

January 26th 2018

Primary Cutaneous T-cell Lymphoma: ALCANZA Trial

January 26th 2018

Role of Novel Therapies in Hodgkin Lymphoma

January 26th 2018

Novel Combinations in Relapsed Hodgkin Lymphoma

January 26th 2018

Hodgkin Lymphoma: Addressing the Elderly Population

January 26th 2018

Hodgkin Lymphoma: Important Findings from CheckMate 205

January 26th 2018